Integumen forms water testing distribution collaboration

The real-time water monitoring AI system will be integrated into Acumen's mobile asset management software for existing wastewater utility and industrial production clients across Asia, North and South America, and Australasia

Integumen -

Integumen PLC (LON:SKIN) has formed an alliance with a specialist supplier to municipal and utility customers in order to broaden distribution for its RAWTest water testing product.

The AIM-listed company’s Rinocloud subsidiary agreed a commercial development partnership with South Africa’s Acumen Software to create a combined offering of Acumen's integrated mobile asset and management software platform with RinoDrive's data analytics, data refining capabilities and RAWTest AI real-time water monitoring service.

READ: Integumen delighted with results of E.Coli detection pilot

RAWTest’s real-time water monitoring AI system will be integrated by Acumen into its mobile asset management software for existing wastewater utility and industrial production clients across Asia, North and South America, and Australasia.

Integumen said it expects a “material contribution” on revenue from this partnership this year as the combined offering is offered to both companies’ respective clients and business partners.

Gerard Brandon, chief executive of Integumen, hailed Acumen for its “sales, marketing and distribution channel directly into government municipal and utility enterprises established over the last 12 years on four continents”.

“This keeps with our global growth strategy of collaborating with complementary products and services into top local and international channel partners with a strong sales track record.”

Acumen president Joao Zoio said combining with Rinocloud’s marketing and financial data analytics offered the “immediate capability to future proof our software platform”.

Quick facts: Integumen

Price: 1.8644 GBX

Market: AIM
Market Cap: £21.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...



Kazia Therapeutics working on moving its flagship Paxalisib drug into...

  Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott after releasing a poster presentation of interim data from the ongoing phase II study of Paxalisib in glioblastoma at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Analysis...

2 hours, 3 minutes ago

2 min read